Advertisement

Topics

BTK Inhibitor Granted Breakthrough Therapy Designation for Mantle Cell Lymphoma

05:00 EDT 3 Aug 2017 | OncoTherapy Network

Acalabrutinib has been granted FDA Breakthrough Therapy Designation for the treatment of patients with mantle cell lymphoma who have relapsed or have received at least one prior therapy.

Original Article: BTK Inhibitor Granted Breakthrough Therapy Designation for Mantle Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "BTK Inhibitor Granted Breakthrough Therapy Designation for Mantle Cell Lymphoma"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...